These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 39247440)
1. Affibody-based molecular probe Hu X; Hu H; Li D; Wang P; Cai J Open Med (Wars); 2024; 19(1):20241027. PubMed ID: 39247440 [TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of Yang Y; Zhao X; Xing Y; Yu T; Zhang J; Wang J Oncol Lett; 2018 Oct; 16(4):5361-5366. PubMed ID: 30250607 [TBL] [Abstract][Full Text] [Related]
3. Radiosynthesis, optimization and pharmacokinetic study of the 99m Tc-labeled human epidermal growth factor receptor 2 affibody molecule probe 99m Tc-(HE) 3 Z HER2:V2. Hu X; Liang Z; Qi L; Li F; Cai X; Cai J Nucl Med Commun; 2023 Apr; 44(4):244-251. PubMed ID: 36598155 [TBL] [Abstract][Full Text] [Related]
4. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467 [TBL] [Abstract][Full Text] [Related]
5. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280 [TBL] [Abstract][Full Text] [Related]
6. Novel small Liang Z; Hu X; Hu H; Wang P; Cai J Front Oncol; 2022; 12():1017737. PubMed ID: 36387113 [TBL] [Abstract][Full Text] [Related]
7. Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [ Facca VJ; Al-Saden N; Ku A; Reilly RM Mol Imaging Biol; 2021 Aug; 23(4):495-504. PubMed ID: 33479914 [TBL] [Abstract][Full Text] [Related]
8. Preclinical Evaluation of Oroujeni M; Rinne SS; Vorobyeva A; Loftenius A; Feldwisch J; Jonasson P; Chernov V; Orlova A; Frejd FY; Tolmachev V Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803361 [TBL] [Abstract][Full Text] [Related]
9. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744 [TBL] [Abstract][Full Text] [Related]
10. Preparation and Evaluation of (99m)Tc-Epidermal Growth Factor Receptor (EGFR)-Peptide Nucleic Acid for Visualization of EGFR Messenger RNA Expression in Malignant Tumors. Zhao X; Wang N; Ren X; Zhang J; Wang J; Han J; Jia L; Liu Y; Zhang Z J Nucl Med; 2014 Jun; 55(6):1008-16. PubMed ID: 24744447 [TBL] [Abstract][Full Text] [Related]
11. In vivo imaging characterization and anticancer efficacy of a novel HER2 affibody and pemetrexed conjugate in lung cancer model. Jiao H; Zhao X; Liu J; Ma T; Zhang Z; Zhang J; Wang J Nucl Med Biol; 2019; 68-69():31-39. PubMed ID: 30578135 [TBL] [Abstract][Full Text] [Related]
12. Preparation and Identification of HER2 Radioactive Ligands and Imaging Study of Breast Cancer-Bearing Nude Mice. Zhang MZ; Guan YX; Zhong JX; Chen XZ Transl Oncol; 2017 Aug; 10(4):518-526. PubMed ID: 28558265 [TBL] [Abstract][Full Text] [Related]
13. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342). Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223 [TBL] [Abstract][Full Text] [Related]
14. Phase I clinical evaluation of Bragina O; Chernov V; Larkina M; Rybina A; Zelchan R; Garbukov E; Oroujeni M; Loftenius A; Orlova A; Sörensen J; Frejd FY; Tolmachev V Theranostics; 2023; 13(14):4858-4871. PubMed ID: 37771776 [TBL] [Abstract][Full Text] [Related]